West Pharmaceutical Services (WST) EBIT Margin (2009 - 2026)

West Pharmaceutical Services has disclosed EBIT Margin across 18 years of filings, most recently posting 20.53% for Q2 2026.

• In Q2 2026, EBIT Margin rose 48.0% year-over-year to 20.53%; the TTM figure through Jun 2026 stood at 20.45% (up 80.0% YoY), while the FY2025 annual figure was 19.03%, down 67.0% from the prior year.
• EBIT Margin came in at 20.53% for Q2 2026 at West Pharmaceutical Services, down from 20.96% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 29.61% in Q2 2022 to a low of 15.33% in Q1 2025.
• Average EBIT Margin over 5 years is 21.59%, with a median of 21.14% recorded in 2024.
• Year-over-year, EBIT Margin plunged 688 bps in 2022 and soared 563 bps in 2026.
• Over 5 years, EBIT Margin stood at 18.3% in 2022, then gained by 20 bps to 21.98% in 2023, then retreated by 3 bps to 21.31% in 2024, then dropped by 9 bps to 19.45% in 2025, then rose by 6 bps to 20.53% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 20.53% in Q2 2026, 20.96% in Q1 2026, and 19.45% in Q4 2025.